

# Obesity and Cancer Survival

**Corrigan McBride, MD**

**Professor of Surgery**

**Director of Bariatric Surgery**

**Chief of General Surgery, Minimally Invasive and Bariatric Surgery, UNMC**

University of Nebraska  
Medical Center



Nebraska  
Medicine

# Disclosure

Food and Beverage-

Medtronic

Davol

Bard

Intuitive

Travel for non-CME events- Medtronic



# Objectives

Impact of Obesity on Cancer Incidence

Impact on Obesity on Cancer Diagnosis and Therapies

Impact of Obesity Therapies on Cancer Survivorship.

What about the Bariatric Surgery and Medicine such as the GLP-1?



# Impact of Obesity on Mortality and Cancer Incidence

University of Nebraska  
Medical Center





Nebraska  
Medicine

# Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults in the UK


Krishnan Bhaskaran, Isabel dos-Santos-Silva, David A Leon, Ian J Douglas, Liam Smeeth



## Obesity is linked to increased mortality



# Non-Cancer diagnosis




# Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults in the UK

Krishnan Bhaskaran, Isabel dos-Santos-Silva, David A Leon, Ian J Douglas, Liam Smeeth

THE LANCET

"Taken together, these findings suggest that high-mortality regions can reap the benefits of the positive and often large for-avoidable burden of the LBM, and that public health interventions may be needed to reduce the burden of the world."




# Effect of Obesity on Life Expectancy at Age 40

	Men		Women	
BMI (kg/m <sup>2</sup> )	Life Expectancy at age 40	Reduction in life expectancy	Life Expectancy at age 40	Reduction in life expectancy
< 18.5	77.9	4.3	79.8	4.5
<b>18.5-24.9</b>	<b>82.2</b>	<b>Referent</b>	<b>84.3</b>	<b>Referent</b>
25.0-29.9	81.2	1.0	83.5	0.8
30.0-34.9	78.7	3.4	81.9	2.4
35.0-39.9	76.2	5.9	79.6	4.7
≥ 40.0	73.1	9.1	76.6	7.7





# 13 cancers are associated with overweight and obesity



# Summary risk estimate per 5 kg/m<sup>2</sup>

Location	Men	Women	Strength of Evidence
Esophageal (adeno)	1.52	1.51	Convincing
Gastric (adeno)	0.97	1.04	Probable
Colorectal (adeno)	1.09-1.24	1.02-1.04	Convincing
Gallbladder	1.09	1.59	Probable
Pancreatic (adeno)	1.13	1.10	Convincing
Liver (HCC)	1.19	1.12	Convincing
Renal	1.24	1.34	Convincing
Breast (post menopausal)		1.12	Convincing
Endometrial		1.59	Convincing
Ovarian		1.06	Probable
Prostate	1.08		Probable

# Obesity impacts Therapy

University of Nebraska  
Medical Center





Nebraska  
Medicine

# The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial



Peter Widschwendter<sup>1††</sup>, Thomas WP Friedl<sup>1†</sup>, Lukas Schwentner<sup>1</sup>, Nikolaus DeGregorio<sup>1</sup>, Bernadette Jaeger<sup>1</sup>, Amelie Schramm<sup>1</sup>, Inga Bekes<sup>1</sup>, Miriam Deniz<sup>3</sup>, Krisztian Lato<sup>1</sup>, Tobias Weissenbacher<sup>2</sup>, Bernd Kost<sup>2</sup>, Ulrich Andergassen<sup>2</sup>, Julia Jueckstock<sup>2</sup>, Julia Neugebauer<sup>2</sup>, Elisabeth Trapp<sup>2</sup>, Peter A. Fasching<sup>3</sup>, Matthias W. Beckmann<sup>3</sup>, Andreas Schneeweiss<sup>4</sup>, Ines Schrader<sup>5</sup>, Brigitte Rack<sup>2</sup>, Wolfgang Janni<sup>1</sup> and Christoph Scholz<sup>3</sup>



# The Impact of Obesity on Breast Cancer Diagnosis and Treatment

Kyuwan Lee<sup>1</sup> • Laura Kruper<sup>2</sup> • Christina M. Dieli-Conwright<sup>1</sup> • Joanne E. Mortimer<sup>3,4</sup>



## 1. Challenges of Diagnosis

1. The incidence of False negative was comparable across BMI
2. Stigma of Obesity decreases patient willingness to seek health care

## 2. Surgical Interventions

1. Trend toward moving to breast conservation therapy
  1. Some studies suggest that the risk of local recurrence is higher in obese patients
  2. Sentinel lymph node identification is lower in women with obesity.
2. Obesity is a higher risk of surgical complications in mastectomy patients

## 3. Systemic therapy

1. Patients with obesity require higher doses of systemic tx to get tumor suppression with some regimens
2. Studies that show less benefit of endocrine therapy after treatment on patients with obesity.



# Weight Stigma

Medical Students and NP students report observing weight shaming and weight bias on their clinical rotations.

While some providers think that this behavior will “motivate” patients to work on their weight and health, the opposite is true.

- Patients who experience health care related weight bias are more likely to exhibit unhealthy eating patters, binge eating, and less likely to engage in physical activity.

Remember Obesity is a Disease

You don't say a 42-year-old cancer patient, it is a 42-year-old patient with cancer

Table 1. People-First Language is critical to reducing bias and discrimination

Example of People-First Language	Example of Non-People-First Language
A 43-y-old female patient with obesity	A 43-y-old obese female patient
A study related to children with obesity	A study of obese children



# Weight Stigma


Table 2. Strategies to reduce obesity bias and stigma: compassionate and respectful communication

## Encouraged terms

Weight  
Unhealthy weight  
Overweight  
Preobesity  
Body mass index  
Excessive energy stores  
Affected by obesity  
Eating habits/nutrition  
Physical activity  
Healthy habits


## Discouraged Terms

Morbidly obese  
Obese  
Fat  
Heaviness  
Large size  
Chubby  
Plump  
Big size  
Diet  
Exercise



Class I obesity  
Class II obesity  
Class III obesity

# Weight bias and health care utilization: a scoping review

Angela S. Alberga<sup>1</sup> , Iyoma Y. Edache<sup>1</sup>, Mary Forhan<sup>2</sup> and Shelly Russell-Mayhew<sup>3</sup>


1. Contemptuous treatment- verbal insults, inappropriate humor, treated less respectfully
2. Attribution of all health issues to excess weight
3. Health provider making assumptions about weight gain
4. Barriers to health care utilization
  1. 7 studies showed avoidance, delay or cancellation of health care services because of
    1. Not wanting to weight
    2. Not wanting to get undressed
    3. Inadequate seating, tables, gowns, BP cuffs, etc
5. Wanting to be seen as a whole person is interpreted as “doctor shopping”






# The multifactorial effect of obesity on the effectiveness and outcomes of cancer therapies

Joanne Lysaght<sup>1</sup> & Melissa J. Conroy<sup>2</sup>



**Fig. 1: Obesity-associated cancers, relative risk, treatment efficacy, toxicities and outcomes.**




# Obesity impacts Co-morbidities

University of Nebraska  
Medical Center



Nebraska  
Medicine



# Cardiovascular disease is the leading cause of death among endometrial cancer patients

Kristy K. Ward \*, Nina R. Shah, Cheryl C. Saenz, Michael T. McHale, Edwin A. Alvarez, Steven C. Plaxe



NCI Surveillance, Epidemiology and End Results(SEER)  
9 registries

Patients from 1973-1988 (so would have 20-year mortality data)

44,145 patients with endometrial cancer

By 2008, 75.3% had died.

96% of patients had known Cause of Death (COD)




# Cardiovascular disease is the leading cause of death among endometrial cancer patients

Kristy K. Ward \*, Nina R. Shah, Cheryl C. Saenz, Michael T. McHale, Edwin A. Alvarez, Steven C. Plaxe



Chart Title



# **Weight Management is an important part of Post Cancer Survivorship**



# Bariatric Surgery

University of Nebraska  
Medical Center



Nebraska  
Medicine



# Lap Sleeve Gastrectomy

Remove ~80% of the stomach

Restricts the quantity of food

Removes the ghrelin producing cells, so not hungry

No foreign body

Laparoscopic, overnight stay

Irreversible

Potential for vitamin deficiency, B vit, Fe

Risks of Leak, DVT/PE, portal vein thrombosis

Weight loss ~20-25% of total body weight



# Lap Gastric Bypass

Gold Standard Operation

Restricts the amount of food

Because no food contacts the antrum, there is a decrease in ghrelin (less hunger) and undigested food hit small intestine faster there is an increase in leptin (early satiety)

Risks- Leak, DVT/PE,  
Long term vitamin def- Fe, B12,  
Ca, Vit D.  
Ulcers-smoking, NSAID, steroids,  
Internal hernia

Weight loss ~25-30% of  
total body weight



# Lap Duodenal Switch, SADI-S

Decrease risks of internal hernia, ulcers, re weight gain

Can take NSAIDS, steroids with much lower risk of ulcers, no dumping with sugar (pylorus in place)

If eat carbs or excessive fat, gas bloating diarrhea.

No dumping.

Increased risk of vitamin deficiencies - need to be on supplementation for life

Weight Loss ~30-35% of total body weight




FIGURE 5

**Migraines**  
57% resolved

**Pseudotumor  
Cerebri**  
96% resolved

**Dyslipidemia  
Hypercholesterolemia**  
63% resolved

**Non-Alcoholic Fatty  
Liver Disease**  
90% improved  
steatosis  
37% resolution of  
inflammation  
20% resolution of  
fibrosis

**Metabolic  
Syndrome**  
80% resolved

**Type II  
Diabetes Mellitus**  
83% resolved

**Polycystic  
Ovarian Syndrome**  
79% resolution of hirsutism  
100% resolution of  
menstrual dysfunction

**Venous Stasis Disease**  
95% resolved

**Quality of Life-**  
improved in  
95% of patients

**Depression**  
55% resolved

**Obstructive  
Sleep Apnea**  
74-98% resolved

**Asthma**  
82% improved  
or resolved

**Cardiovascular  
Disease**  
82% risk reduction

**Hypertension**  
52-92% resolved


**GERD**  
72-98% resolved

**Stress Urinary  
Incontinence**  
44-88% resolved

**Degenerative  
Joint Disease**  
41-76% resolved

**Gout**  
77% resolved

**Mortality-**  
89% reduction in  
5-year mortality



# Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity

Ali Aminian, MD; Alexander Zajichek, MS; David E. Arterburn, MD, MPH; Kathy E. Wolski, MPH; Stacy A. Brethauer, MD; Philip R. Schauer, MD; Michael W. Kattan, PhD; Steven E. Nissen, MD


2287 Bariatric patients with Type 2 Diabetes mellitus

matched 1:5 to 11435 Control patients with Type 2 Diabetes mellitus




# Metabolic Surgery vs. Usual Care

## All-Cause Mortality




## Heart Failure




# Metabolic Surgery vs. Usual Care

## Coronary Artery Disease




## Cerebrovascular Disease




# Metabolic Surgery vs. Usual Care

## Nephropathy




## Atrial Fibrillation





# Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis

Ali Aminian, MD; Abbas Al-Kurd, MD; Rickesha Wilson, MD; James Bena, MS; Hana Fayazzadeh, MD; Tavankit Singh, MD; Vance L. Albaugh, MD, PhD; Faiz U. Shariff, MD; Noe A. Rodriguez, MD; Jian Jin, MS; Stacy A. Brethauer, MD, MBA; Srinivasan Dasarathy, MD; Naim Alkhouri, MD; Philip R. Schauer, MD; Arthur J. McCullough, MD; Steven E. Nissen, MD




# Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity

Ali Aminian, MD; Rickesha Wilson, MD; Abbas Al-Kurd, MD; Chao Tu, MS; Alex Milinovich, BA; Matthew Kroh, MD; Raul J. Rosenthal, MD; Stacy A. Brethauer, MD; Philip R. Schauer, MD; Michael W. Kattan, PhD; Justin C. Brown, PhD; Nathan A. Berger, MD; Jame Abraham, MD; Steven E. Nissen, MD

## Surgical Procedures and Long-term Effectiveness in Neoplastic Disease Incidence and Death (SPLENDID)

### Metabolic Surgical Procedures (N=5053)



Gastric Bypass


N=3348 (66%)

Sleeve Gastrectomy

N=1705 (34%)



# Surgical Procedures and Long-term Effectiveness in Neoplastic Disease Incidence and Death (SPLENDID)



# Surgical Procedures and Long-term Effectiveness in Neoplastic Disease Incidence and Death (SPLENDID)



The better the weight loss the lower the cumulative risk of cancer



# **Dose Dependent Response**


**The More the Weight  
Loss,**

**The Better the Outcomes**



# Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants

Nicholas L Syn\*, David E Cummings\*, Louis Z Wang\*, Daryl J Lin\*, Joseph J Zhao, Marie Loh, Zong Jie Koh, Claire Alexandra Chew, Ying Ern Loo, Bee Choo Tai, Guowei Kim, Jimmy Bok-Yan So, Lee M Kaplan, John B Dixon, Asim Shabbir



Median life expectancy gain after surgery:

- Total 6.1 years (95% CI 5.2-6.9)
- Without diabetes: 5.1 years (2.0-9.3)
- With diabetes: 9.3 years (95% CI 7.1-11.8)



**There are no studies that talk about Bariatric Surgery after a primary cancer diagnosis to decrease risk of recurrence or a second primary.**



# What about Medical Weight Loss in the GLP-1 era?


University of Nebraska  
Medical Center



Nebraska  
Medicine




# Semaglutide vs Tirzepatide



Bars represent mean changes in body weight from baseline to the time point among the propensity score matched population of patients still receiving treatment. The whiskers represent 95% CIs.



# Obesity Treatment 1960-2024



# Barriers to GLP-1 Therapy

## Cost

- Lack of insurance coverage

## Supply chain issues

## Side effects

- Nausea
- Abdominal pain
- Constipation

## Contraindications

- Pancreatitis
- MEN 2A or 2B
- Medullary Thyroid Cancer



# Impact of Prior Bariatric Surgery on Cancer

University of Nebraska  
Medical Center



Nebraska  
Medicine

# Gastroesophageal Cancer After Gastric Bypass Surgeries: a Systematic Review and Meta-analysis

Rodrigue Chemaly<sup>1,2</sup> · Samer Diab<sup>1</sup> · Georges Khazen<sup>3</sup> · Georges Al-Hajj<sup>1,2</sup>

Gastroesophageal adenocarcinoma after gastric bypass.


52 cases identified

30 cancers in the distal esophagus/ gastric pouch

22 cancers in the excluded stomach

Symptoms:

- Abdominal distention (5)
- Abdominal pain (23)
- Anemia(6)
- Anorexia/Early satiety (2)
- Constipation (1)
- Dysphagia (16)
- GERD(1)
- Melena(5)
- N/V(10)
- Weight loss (13)



# Risk of Esophageal and Gastric Cancer After Bariatric Surgery

Andrea Lazzati, MD, PhD<sup>1,2</sup>; Tigran Poghosyan, MD, PhD<sup>3,4,5</sup>; Marwa Touati, MS<sup>6</sup>; [et al](#)

National discharge database in France (PMSI)- 2010-2019

303,709 had bariatric surgery and at least a 2 year follow up with no cancer diagnosis

Matched 1:2 with obese patients who did not have MBS

	<b>MBS</b>	<b>Control</b>	<b>P value</b>
Follow up (years)	6.06	5.62	
Esophageal CA	26	86	
case per 100,000	1.8	2.3	0.05
Gastric cancer	57	168	
case per 100,000	3.3	4.6	0.04
EG CA Total	83	254	
case per 100,000	4.9	6.9	0.005

# Therapeutic Challenges

University of Nebraska  
Medical Center



Nebraska  
Medicine



Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures – 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists

Nutrient	Amount	Risk of deficiency
Protein	60-120 gm/day	1-10%
B1 (thiamine)	50-100 mg daily	<1-49%
B12 (cobalamin)	350-1000 µg daily	RYGB <20%, SG 4-20%
Folate (folic acid)	400-1000 µg daily	65%
Iron	40-60 mg elemental daily	SG <18%, RYGB 20-55%, DS 8-50%
Calcium/Vit D	Ca-1200-2400 mg/d Vit D 3000 IU daily	Up to 100%
Vit A	5000-10000IU/d	DS 70
Vit E	15 mg/d	Uncommon
Vit K	90-300 µg daily	Uncommon
Zinc	8-22 mg daily	SG <19%, RYGB 40%, DS up to 70%
Copper	1-2 mg daily	RYGB 10-20% DS up to 90%







# Distal esophagus/GEJ Cancer



Distal esophagus and proximal stomach are removed and the remaining stomach is based on a sleeve gastrectomy had eliminated the gastric tube



# Distal esophagus/GEJ Cancer




Esophagogastrostomy

With a J tube into the  
Roux limb



# Distal esophagus/GEJ Cancer



Complete gastrectomy


EJ with the pre-existing  
Roux limb


J tube into biliary limb  
or common channel

Roux needs to be at  
least 60-100 cm to  
prevent bile reflux



# Pancreatoduodenectomy after Roux-en-Y gastric bypass surgery: Single-center experience and literature review

Sheraz Yaqub <sup>1</sup>, Tore Tholfsen<sup>2</sup>, Anne Waage<sup>3</sup>, Dyre Kleive<sup>4</sup>, and Knut Jørgen Labori<sup>5</sup>



6 patient (788) had a RY Gastric bypass for obesity and later developed pancreatic CA


Presenting symptoms: Pain (50%)  
Jaundice (50%)




Median 5.5 years after RYGB

Median follow up 60 mo.




# Pancreatoduodenectomy after Roux-en-Y gastric bypass surgery: Single-center experience and literature review

Sheraz Yaqub <sup>1</sup>, Tore Tholfson<sup>2</sup>, Anne Waage<sup>3</sup>, Dyre Kleive<sup>4</sup>, and Knut Jørgen Labori<sup>5</sup>



RYGB Anatomy

# Treatment Approach for Obesity



# Conclusion

Obesity contributes to mortality

The higher the BMI the shorter the life expectancy

Obesity is linked to multiple malignancies

Heavier patients can be more difficult to diagnose, and treat

Obesity related co-morbidities can contribute to complications and long term mortality

Bariatric Surgery decreases the risk of getting and dying of cancer.

Bariatric Medicine and Surgery can decrease the risk of dying of obesity related complications

Surgery is more effective and cost effective.



University of Nebraska  
Medical Center



Nebraska  
Medicine

